Get the Stockscreener App
0.517
0.08%
0.0004
Pre-market:
.50
-0.017
-3.29%
AIM ImmunoTech Inc stock is traded at $0.517, with a volume of 46,458.
It is up +0.08% in the last 24 hours and down -13.11% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$0.5166
Open:
$0.5228
24h Volume:
46,458
Relative Volume:
0.01
Market Cap:
$4.21M
Revenue:
$88,000
Net Income/Loss:
$-13.96M
P/E Ratio:
-0.0777
EPS:
-6.6545
Net Cash Flow:
$-11.34M
1W Performance:
-0.58%
1M Performance:
-13.11%
6M Performance:
-71.09%
1Y Performance:
+445.33%
1-Day Range:
$0.5101
$0.5228
1-Week Range:
$0.5021
$0.5359
52-Week Range:
$0.475
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.517 | 4.21M | 88,000 | -13.96M | -11.34M | -6.6545 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
AIM ImmunoTech Inc Stock (AIM) Latest News
AIM ImmunoTech (AIM) price target decreased by 54.50% to 10.20 - MSN
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech Inc. Common Stock (NY: AIM - FinancialContent
AIM ImmunoTech Inc. (AIM) posts wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading.Most Watched Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - The National Law Review
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP - ADVFN
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer By Investing.com - Investing.com Australia
AIM ImmunoTech (AIM) Advances Pancreatic Cancer Treatment Plans - GuruFocus
AIM ImmunoTech IncExpects Next Duripanc St - Moomoo
AIM ImmunoTech Starts Late-Stage Trial of Ampligen in Pancreatic Cancer - Moomoo
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer - Investing.com
AIM ImmunoTech Enters Pivotal Value Inflection Phase with - GlobeNewswire
AIM ImmunoTech Inc. announces that its core drug Ampligen® has reached a critical value inflection point in the field of pancreatic cancer treatment. - Bitget
AIM ImmunoTech Provides Routine Update on Annual Filings - ChartMill
AIM ImmunoTech Inc. Reports Audit Findings with Going Concern Emphasis and Positive Clinical Trial Progress for Ampligen in Pancreatic Cancer Treatment - Quiver Quantitative
Aim Immunotech Provides Routine Update On Annual Filings - TradingView
AIM ImmunoTech Inc. 8-K Filing Details Equity Distribution Agreement Amendment and NYSE American Listing - Minichart
AIM ImmunoTech Expands At-The-Market Equity Offering Capacity - TipRanks
AIM ImmunoTech's ATM Expansion Hides Ongoing Liquidity Stress and Shareholder Squeeze Risk - Bitget
AIM ImmunoTech amends equity distribution agreement to remove share sale limit - Investing.com Australia
AIM ImmunoTech Expands ATM Equity Program With Maxim, Removing Prior $3 Million Cap - TradingView
AIM ImmunoTech (NYSE: AIM) lifts cap on at-the-market stock sales - Stock Titan
AIM ImmunoTech (NYSE American: AIM) ups ATM capacity to $3.41M under S‑3 - Stock Titan
Constellation Brands To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
AIM Stock Target Price Lowered by Ascendiant Capital | AIM Stock News - GuruFocus
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - marketscreener.com
AIM ImmunoTech CEO to take live investor questions on April 16 - Stock Titan
AIM SEC FilingsAim Immunotech 10-K, 10-Q, 8-K Forms - Stock Titan
AIM ImmunoTech Inc (AIM) Stock Price, Trades & News - GuruFocus
AIM Stock Analysis: AIM ImmunoTech Inc. hits 0.59 on 8.18 percent biotech rally - Xã Thanh Hà
AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is AIM ImmunoTech (AIM) stock outpacing its medical peers this year? - MSN
AIM PE Ratio & Valuation, Is AIM Overvalued - Intellectia AI
AIM Stock Analysis: AIM ImmunoTech Inc. biotech performance update at 0.59 after minor daily advance - Cổng thông tin điện tử Tỉnh Sơn La
AIM ImmunoTech 2025 Annual Report: Focus on Ampligen for Pancreatic Cancer, Clinical Trials, and R&D Highlights - Minichart
AIM ImmunoTech 10-K: $0.09M Revenue, $(8.62) EPS, $13.96M Net Loss - TradingView — Track All Markets
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Going concern risk and oncology plans at AIM ImmunoTech (AIM) detailed - Stock Titan
What's going on with AIM ImmunoTech stock Friday? - msn.com
AIM ImmunoTech Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Earnings Scheduled For March 24, 2026 - Sahm
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Insider Monkey
If You Invested $1,000 in Aim Immunotech (AIM) - Stock Titan
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):